Endothelin-1

Overview

Endothelin-1 (ET-1) is a 21-amino-acid peptide produced primarily by vascular endothelial cells and the most potent vasoconstrictor identified in mammalian physiology. Discovered in 1988 by Masashi Yanagisawa and colleagues at the University of Tsukuba, ET-1 was isolated from porcine aortic endothelial cell culture supernatant and was found to produce sustained, long-lasting vasoconstriction orders of magnitude more potent than angiotensin II.

Endothelin-1 is the predominant member of the endothelin family, which includes three isoforms:

• Endothelin-1 (ET-1) — the most abundant isoform, produced by endothelial cells, cardiomyocytes, renal mesangial cells, neurons, and hepatic stellate cells
• Endothelin-2 (ET-2) — expressed in the intestine, ovary, and uterus
• Endothelin-3 (ET-3) — primarily expressed in the brain, gastrointestinal tract, and adrenal gland; involved in neural crest development

Under normal physiological conditions, ET-1 functions as a paracrine mediator of vascular tone, acting on underlying smooth muscle to produce vasoconstriction balanced by the release of vasodilatory factors (nitric oxide, prostacyclin). In pathological states, dysregulated ET-1 overproduction and/or impaired counter-regulatory mechanisms contribute to sustained vasoconstriction, vascular remodeling, inflammation, and fibrosis — processes central to pulmonary arterial hypertension (PAH), heart failure, chronic kidney disease, and systemic sclerosis.

The development of endothelin receptor antagonists (ERAs) has been one of the major advances in pulmonary hypertension therapeutics:

• Bosentan (Tracleer) — dual ET_A/ET_B antagonist (FDA approved 2001)
• Ambrisentan (Letairis) — selective ET_A antagonist (FDA approved 2007)
• Macitentan (Opsumit) — dual ET_A/ET_B antagonist with improved tissue penetration (FDA approved 2013)

Structure and Sequence

Human ET-1 sequence: Cys-Ser-Cys-Ser-Ser-Leu-Met-Asp-Lys-Glu-Cys-Val-Tyr-Phe-Cys-His-Leu-Asp-Ile-Ile-Trp

• Molecular formula: C₁₀₉H₁₅₉N₂₃O₃₂S₅
• Molecular weight: approximately 2,492 g/mol
• Gene: EDN1 (chromosome 6p24.1)

Key structural features:

• Two disulfide bridges: Cys1-Cys15 and Cys3-Cys11 form a rigid bicyclic ring structure that constrains the N-terminal region
• C-terminal tail: The free C-terminal hexapeptide tail (His-Leu-Asp-Ile-Ile-Trp) extends from the ring and is essential for receptor binding; the C-terminal tryptophan is critical for biological activity
• Structural similarity to sarafotoxins: The endothelin peptides share remarkable structural homology with sarafotoxins, venom peptides from the Israeli burrowing asp (Atractaspis engaddensis), suggesting convergent evolution of a potent vasoactive scaffold

Biosynthesis (multi-step processing):

1. Preproendothelin-1 (212 amino acids) — translated from EDN1 mRNA
2. Big endothelin-1 (38 amino acids) — generated by furin and other proprotein convertases from preproendothelin-1
3. Endothelin-1 (21 amino acids) — produced by endothelin-converting enzymes (ECE-1, ECE-2) cleaving the Trp21-Val22 bond of big ET-1. This conversion step is rate-limiting and is a potential therapeutic target.

Regulation of synthesis: ET-1 gene expression and release are stimulated by:

• Angiotensin II, vasopressin, thrombin, transforming growth factor-beta
• Hypoxia (via hypoxia-inducible factor pathway)
• Shear stress (complex — low/disturbed shear promotes ET-1; laminar shear suppresses it)
• Inflammatory cytokines (IL-1, TNF-alpha)

And suppressed by:

• Nitric oxide, prostacyclin, atrial natriuretic peptide, BNP
• High laminar shear stress
• Estrogen

Mechanism of Action

Endothelin Receptor Signaling

ET-1 acts through two G-protein coupled receptors with distinct distributions and functions:

ET_A Receptor:

• Predominantly expressed on vascular smooth muscle cells, cardiomyocytes, and fibroblasts
• Binds ET-1 >> ET-3 (highly selective for ET-1)
• Coupled to Gq/G11 proteins: activates phospholipase C, increases intracellular calcium, activates protein kinase C
• Primary mediator of vasoconstriction, cell proliferation, and pro-fibrotic signaling
• Promotes vascular smooth muscle contraction through calcium-dependent and calcium-sensitization (Rho kinase) mechanisms
• Stimulates smooth muscle cell proliferation and hypertrophy contributing to vascular remodeling
• Promotes cardiac myocyte hypertrophy and fibroblast collagen synthesis

ET_B Receptor:

• Expressed on endothelial cells (where it mediates clearance and vasodilation) and smooth muscle cells (where it mediates vasoconstriction)
• Binds ET-1 = ET-2 = ET-3 (non-selective among endothelins)
• Dual function depending on cell type:
  • On endothelial cells: stimulates NO and prostacyclin release, producing vasodilation and counterbalancing ET_A-mediated vasoconstriction
  • On smooth muscle cells: mediates vasoconstriction (particularly in venous capacitance vessels and pulmonary vasculature)
• Clearance receptor: Endothelial ET_B receptors internalize and clear circulating ET-1, particularly in the pulmonary vasculature (the lung clears approximately 50% of circulating ET-1 in a single pass)

Pathological Effects

In disease states, the balance between ET-1's pathological (ET_A-mediated) and protective (endothelial ET_B-mediated) effects shifts toward pathology:

Vasoconstriction and vascular remodeling:

• Sustained ET_A activation produces prolonged vasoconstriction lasting hours (compared to minutes for most vasoconstrictors)
• Chronic ET-1 stimulation promotes smooth muscle cell proliferation and migration, intimal hyperplasia, and adventitial fibrosis
• In pulmonary arteries, these effects drive the progressive vascular obliteration characteristic of PAH

Cardiac effects:

• Positive inotropic effect (acutely) through increased intracellular calcium
• Chronically promotes pathological cardiac hypertrophy through calcineurin/NFAT and MAPK pathways
• Stimulates cardiac fibrosis through fibroblast activation and collagen deposition
• ET-1 levels are markedly elevated in heart failure and correlate with disease severity

Renal effects:

• Constriction of afferent and efferent glomerular arterioles, reducing renal blood flow
• Mesangial cell contraction reduces glomerular filtration
• Promotes sodium retention and contributes to fluid overload
• Stimulates renal fibrosis in chronic kidney disease

Inflammatory and fibrotic effects:

• Promotes inflammatory cell adhesion to endothelium
• Stimulates cytokine and chemokine release
• Activates fibroblasts and myofibroblasts, promoting tissue fibrosis across multiple organs

Research Summary

Area	Study/Context	Key Finding	Reference
Pulmonary arterial hypertension	BREATHE-1 (bosentan)	Bosentan improved exercise capacity and hemodynamics in PAH; first oral ERA approved	Rubin et al., 2002 (NEJM)
PAH long-term outcomes	SERAPHIN (macitentan)	Macitentan reduced morbidity/mortality composite in PAH over long-term treatment	Pulido et al., 2013 (NEJM)
Heart failure biomarker	Multiple cohort studies	ET-1 levels are elevated 2-5 fold in heart failure and independently predict mortality	Pacher et al., 1993; Wei et al., 1994
Heart failure therapy	ENABLE trials (bosentan)	ERA therapy in heart failure showed early fluid retention and no net mortality benefit; ERAs not indicated for heart failure	Kalra et al., 2002
Systemic sclerosis	Observational	ET-1 overproduction drives digital ischemia and pulmonary vascular disease in systemic sclerosis; ERAs reduce digital ulcers	Korn et al., 2004
Diabetic nephropathy	ASCEND trial (avosentan)	ERA showed reduced proteinuria but increased fluid retention and heart failure events	Mann et al., 2010
Subarachnoid hemorrhage	Clazosentan trials	ET_A antagonism reduced cerebral vasospasm after SAH but did not consistently improve clinical outcomes	Macdonald et al., 2012

Pharmacokinetics

Endogenous ET-1:

• Plasma half-life: Approximately 4-7 minutes; rapidly cleared by ET_B receptor-mediated internalization in the pulmonary vasculature
• Plasma levels: 1-5 pg/mL in healthy individuals; elevated 2-5 fold in heart failure, PAH, and renal disease
• Secretion: Predominantly abluminal (toward smooth muscle) rather than luminal (into blood), making plasma levels a significant underestimate of local tissue concentrations
• Pulmonary clearance: The lung removes approximately 50% of circulating ET-1 per transit, primarily through endothelial ET_B receptor binding
• Renal clearance: Minor contribution to systemic ET-1 elimination

Endothelin receptor antagonists:

• Bosentan: Oral bioavailability approximately 50%; half-life approximately 5 hours; hepatically metabolized via CYP3A4 and CYP2C9; requires monthly liver function monitoring (hepatotoxicity risk 10-14%)
• Ambrisentan: Oral bioavailability approximately 69%; half-life approximately 15 hours; less hepatotoxic than bosentan; glucuronidation is the primary metabolic pathway
• Macitentan: Oral half-life approximately 16 hours (active metabolite approximately 48 hours); designed for improved tissue penetration and sustained receptor occupancy; lower hepatotoxicity risk

Common Discussion Topics

Pulmonary arterial hypertension and ERAs: PAH is the paradigmatic ET-1-driven disease. The pulmonary vasculature is exquisitely sensitive to ET-1, and ET-1 levels in PAH patients are markedly elevated. ERAs are a cornerstone of PAH combination therapy, typically used with phosphodiesterase-5 inhibitors (sildenafil, tadalafil) and prostacyclin pathway agents. The choice between selective ET_A antagonists (ambrisentan) and dual ET_A/ET_B antagonists (bosentan, macitentan) remains debated — selective ET_A blockade preserves the beneficial ET_B-mediated clearance and vasodilation, while dual blockade provides more complete ET pathway suppression.

ET-1 in heart failure — therapeutic failure: Despite ET-1 being a validated biomarker and pathological mediator in heart failure, ERA therapy has consistently failed in heart failure trials. The primary issue is fluid retention — ET_B receptor blockade in the kidney impairs sodium excretion, worsening the congestion that ERAs were intended to alleviate. This failure highlights the distinction between a biomarker's prognostic value and its viability as a therapeutic target.

Teratogenicity of ERAs: All endothelin receptor antagonists are teratogenic (FDA category X), based on severe craniofacial and cardiovascular malformations observed in animal studies. This necessitates strict pregnancy prevention programs (REMS for bosentan) and limits ERA use in women of childbearing potential.

ET-1 and the endothelial balance: ET-1 exemplifies the concept of endothelial homeostasis. Healthy endothelium maintains a balance between vasoconstrictive (ET-1) and vasodilatory (nitric oxide, prostacyclin) mediators. Endothelial dysfunction — caused by hypertension, diabetes, smoking, or aging — shifts this balance toward ET-1 predominance, contributing to vascular disease progression.

Relationship to the RAAS: ET-1 and angiotensin II engage in positive feedback — angiotensin II stimulates ET-1 production, and ET-1 stimulates angiotensin-converting enzyme expression. This cross-amplification contributes to the combined benefit of RAAS blockade (ACE inhibitors, ARBs) and ERA therapy in some vascular diseases.

Dosing Protocols

As an endogenous vasoconstrictor peptide, endothelin-1 is not typically administered exogenously in clinical practice. It is primarily studied as a biomarker of endothelial dysfunction and through receptor-targeted interventions. The therapeutic relevance of endothelin biology is realized through endothelin receptor antagonists (ERAs) such as bosentan, ambrisentan, and macitentan, which are FDA-approved for pulmonary arterial hypertension. Endothelin-1 itself is used in research settings for vascular function studies and provocation testing.

Related Compounds

• BNP — natriuretic peptide that functionally opposes ET-1's vasoconstrictive and fluid-retaining effects
• Bradykinin — vasodilatory peptide with opposing vascular effects; both are regulated by ACE
• CGRP — potent vasodilatory neuropeptide that functionally counterbalances ET-1-mediated vasoconstriction